Guillain-Barré syndrome (GBS) is a rare, acute immune-mediated polyradiculoneuropathy that accounts for an estimated 100,000 new cases annually worldwide. The typical clinical manifestations of the disease are progressive, ascending paralysis, classically involving bilateral upper and lower extremities. In most patients, the acute onset of neurological symptoms is preceded by an infectious respiratory or gastrointestinal illness. The case is presented of a 50-year-old man who was transferred to an intensive care unit from the Department of Neurology, due to a worsening state of bilateral weakness of limbs, with symptoms of respiratory failure and hemodynamic instability. Guillain-Barré syndrome was diagnosed in the previous clinic on the basis of the typical symptoms and results of cerebrospinal fluid, in which albuminocytological dissociation was detected. Furthermore, two weeks previously, the patient had been infected with COVID-19.
Paluch Z, Biedroń N, Kaczmarska A, Sysiak-Sławecka J. Guillain-Barré syndrome associated with COVID-19 infection – case report and literature review. J Pre-Clin Clin Res. 2023; 17(2): 117–120. doi: 10.26444/jpccr/166116
Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa2001017.
Piwowarczyk P, Szczukocka M, Kutnik P, et al. Risk factors and outcomes for acute respiratory failure in coronavirus disease 2019: An observational cohort study. Adv Clin Exp Med. 2021;30(2):165–171. doi:10.17219/acem/130603.
Rogers JP, Watson CJ, Badenoch J, et al. Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives. J Neurol Neurosurg Psychiatry. 2021;92(9):932–941. doi: 10.1136/jnnp-2021–326405.
Flores-Silva FD, García-Grimshaw M, Valdés-Ferrer SI, et al. Neurologic manifestations in hospitalized patients with COVID-19 in Mexico City. PLoS One. 2021;16(4):e0247433. doi: 10.1371/journal.pone.0247433.
Collantes MEV, Espiritu AI, Sy MCC, et al. Neurological Manifestations in COVID-19 Infection: A Systematic Review and Meta-Analysis. Can J Neurol Sci. 2021;48(1):66–76. doi: 10.1017/cjn.2020.146.
Pimentel V, Luchsinger VW, Carvalho GL, et al. Guillain-Barré syndrome associated with COVID-19: A systematic review. Brain Behav Immun Health. 2023;28:100578. doi:10.1016/j.bbih.2022.100578.
Goodfellow JA, Willison HJ. Guillain-Barré syndrome: a century of progress. Nat Rev Neurol. 2016;12(12):723–731. doi: 10.1038/nrneurol.2016.172.
Babazadeh A, Mohseni Afshar Z, Javanian M, at al. Influenza Vaccination and Guillain-Barré Syndrome: Reality or Fear. J Transl Int Med. 2019;31;7(4):137–142. doi: 10.2478/jtim-2019–0028.
Nguyen TP, Taylor RS. Guillain Barre Syndrome. 2022 Jul 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 30335287.
Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021 Mar 27;397(10280):1214–1228. doi: 10.1016/S0140–6736(21)00517–1.
Malek E, Salameh J. Guillain-Barre Syndrome. Semin Neurol. 2019;39(5):589–595. doi: 10.1055/s-0039–1693005.
Ariño H, Heartshorne R, Michael BD, et al. Neuroimmune disorders in COVID-19. J Neurol. 2022;269(6):2827–2839. doi: 10.1007/s00415–022–11050-w.
Dangayach NS, Newcombe V, Sonnenville R. Acute Neurologic Complications of COVID-19 and Postacute Sequelae of COVID-19. Crit Care Clin. 2022 Jul;38(3):553–570. doi: 10.1016/j.ccc.2022.03.002.
Ahmad SJ, Feigen CM, Vazquez JP, et al. Neurological Sequelae of COVID-19. J Integra Neurosci. 2022;6;21(3):77. doi: 10.31083/j.jin2103077.
Berra E, Fundarò C, Chimento P, et al. Unusual sensory-motor neuropathies in post-COVID-19 patients admitted in rehabilitation hospitals: a case-series. Eur J Phys Rehabil Med. 2022;58(4):655–658. doi:10.23736/S1973–9087.21.06663–6.
Piwowarczyk P, Szczukocka M, Cios W, et al. Population Pharmacokinetics and Probability of Target Attainment Analysis of Nadroparin in Different Stages of COVID-19. Clin Pharmacokinet. 2023;1–13. doi:10.1007/s40262–023–01244–4.
Abolmaali M, Rezania F, Behnagh AK, et al. Guillain-Barré syndrome in association with COVID-19 vaccination: a systematic review. Immunol Res. 2022;70(6):752–764. doi: 10.1007/s12026–022–09316–6. Epub 2022 Sep 13. PMID: 36098903; PMCID: PMC9469827.
Aladawi M, Elfil M, Abu-Esheh B, et al. Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review. Can J Neurol Sci. 2022;49(1):38–48. doi:10.1017/cjn.2021.102.
Abu-Rumeileh S, Abdelhak A, Foschi M, et al. Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol 2021;268:1133–1170 doi:10.1007/s00415–020–10124-x.
Bentley SA, Ahmad S, Kobeissy FH, et al. Concomitant Guillain-Barré Syndrome and COVID-19: A Meta-Analysis of Cases. Medicina (Kaunas). 2022;58(12):1835. doi:10.3390/medicina58121835.
Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671–683. doi: 10.1038/s41582–019–0250–9.
Doets AY, Verboon C, van den Berg B, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018;141(10):2866–2877. doi: 10.1093/brain/awy232.
Mehta S. Neuromuscular disease causing acute respiratory failure. Respir Care. 2006;51(9):1016–21; discussion 1021–3. PMID: 16934165.
Gong Q, Liu S, Xiao Z, et al. Elevated Blood and Cerebrospinal Fluid Glucose Levels Affect the Severity and Short-Term Prognosis of Guillain-Barré Syndrome. Neurol Res. 2021;44:121–127. doi: 10.1080/01616412.2021.1965337.
Shang P, Feng J, Wu W, et al. Intensive Care and Treatment of Severe Guillain-Barré Syndrome. Front Pharmacol. 2021;27;12:608130. doi: 10.3389/fphar.2021.608130.
Querol L, Lleixà C. Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP. Neurotherapeutics. 2021;18(4):2222–2235. doi: 10.1007/s13311–021–01117–3.
Rypulak E, Borys M, Piwowarczyk P, et al. Successful treatment of anti-NMDA receptor encephalitis with a prompt ovarian tumour removal and prolonged course of plasmapheresis: A case report. Mol Clin Oncol. 2016;5(6):845–849. doi: 10.3892/mco.2016.1054.
Liu S, Dong C, Ubogu EE. Immunotherapy of Guillain-Barré syndrome. Hum Vaccin Immunother. 2018;14(11):2568–2579. doi: 10.1080/21645515.2018.1493415.
Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012;11;(7):CD002063. doi: 10.1002/14651858.CD002063.pub5..
Hughes RA, Brassington R, Gunn AA, et al. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2016;24;10(10):CD001446. doi: 10.1002/14651858.CD001446.pub5.
Zhang X, Xia J, Ye H. Effect of Tripterygium polyglycoside on interleukin-6 in patients with Guillain-Barre syndrome. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000;20(5):332–4. Chinese. PMID: 11789240.
Wollinsky KH, Hülser PJ, Brinkmeier H, et al. CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology. 2001;11;57(5):774–80. doi: 10.1212/wnl.57.5.774.
Donofrio PD. Immunotherapy of idiopathic inflammatory neuropathies. Muscle Nerve. 2003;28(3):273–92. doi: 10.1002/mus.10402. PMID: 12929187.
Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database System Rev. 2017’27;2(2):CD001798. doi: 10.1002/14651858.CD001798.pub3.
Shang P, Zhu M, Baker M, et al. Mechanical ventilation in Guillain-Barré syndrome. Expert Rev Clin Immunol. 2020;16:1053–64. doi: 10.1080/1744666X.2021.1840355.